WADA 2027 Peptide Changes: What Takes Effect January 1

The 2027 WADA Prohibited List takes effect on January 1, 2027. It adds peptides to the examples in S0 and explicitly names SLU-PP-332 and SLU-PP-915 under metabolic modulators in S4. Semaglutide and tirzepatide remain in the separate Monitoring Program¹²³.

As of October 2026, this is an upcoming rule set. Use the 2026 peptide guide for the current year and this page to prepare for the transition. A publication date in September does not move the effective date forward.

What changes for peptides in S0?

S0 covers pharmacological substances that are not addressed by a later section and lack current approval from a governmental health regulator for human therapeutic use. The 2027 wording explicitly includes peptides among its examples. BPC-157 is still specifically named in that class¹.

This is not a statement that every molecule called a peptide is prohibited. Approval status and the other list categories still matter. It is also not an announcement that previously unapproved research compounds were permitted until this wording appeared. WADA describes the addition as clarification in its explanatory material².

For a buyer, the distinction is straightforward: a vendor does not establish sporting eligibility by saying that its exact product name is missing from the examples. The substance and applicable category have to be assessed. A marketing phrase such as recovery support is not a category exemption.

SLU-PP-332 becomes an explicit S4 example

The new list names SLU-PP-332, SLU-PP-915 and related substances under S4.4.1. These are metabolic modulators prohibited at all times. The explanatory note identifies the addition rather than presenting these compounds as a newly approved route to endurance enhancement¹².

Our SLU-PP-332 evidence review addresses the animal research and absence of established human use. The 2027 listing is an anti-doping rule, not evidence that the compound works in people, has a safe dose or is available as a legitimate prescription medicine.

Do not infer a grace period from the new named example. The current-year classification must still be checked under the 2026 rules. The practical outcome for a tested athlete is to resolve status before use, rather than trying to calculate a last permissible date from a headline about next year's list.

Familiar growth-hormone peptides remain covered

The official 2027 document continues to name sermorelin, tesamorelin, CJC-1295 and ipamorelin in the growth-hormone releasing-factor categories. It also lists thymosin-beta-4 and derivatives such as TB-500 among growth factors and growth-factor modulators¹. These are not made acceptable by being discussed in a clinic instead of a research-vendor catalog.

For practical comparison, the question about a compound's benefit belongs beside the question about eligibility. The sermorelin athletic-recovery review examines the former. The official WADA list and the relevant anti-doping organization answer the latter. Neither answer substitutes for the other.

A classification label should always retain its year. If a summary, screenshot or product page omits the effective date, return to the official document before relying on it. A search result can surface a prior year's information long after a new list is published.

Semaglutide and tirzepatide are monitored

The 2027 Monitoring Program includes semaglutide and tirzepatide for in- and out-of-competition monitoring. WADA explains that monitored substances are not on the Prohibited List; the program gathers information about patterns of use³.

Monitoring therefore does not mean prohibited, approved for sport by a clinic, or suitable for weight cutting. It answers a narrower anti-doping question about the listed substances. A combination product still needs every ingredient checked, and a person taking medication still needs individualized medical care.

For the clinical differences, use tirzepatide versus semaglutide. For treatment outcomes relevant to training, read the muscle-loss evidence. Neither article should be read as an invitation to use a prescription drug for competition preparation.

A prescription and an exemption are separate

A doctor's willingness to prescribe does not itself resolve anti-doping eligibility. Tell the prescriber that you compete under anti-doping rules and identify the governing organization. That conversation needs to occur before a new medication or a clinic program begins, not after a test notification.

If a prohibited medication is medically necessary, ask the appropriate anti-doping organization about the therapeutic use exemption process. USADA directs athletes to its medication resources and TUE information; its published guidance also cautions that Global DRO cannot be assumed to list every research peptide or trade name⁴.

Do not use this article to decide whether an exemption will be granted. An article cannot review the clinical record or the rules for your sport. The useful outcome is that the clinician and athlete know who must answer the question and which exact product is being assessed.

What to have ready when checking a product

Gather the ingredient list, brand or product name, route, intended use and the country where it is supplied. Keep the original labeling rather than relying only on a sales description. If the product is a blend, list each ingredient individually; a familiar name in large type does not describe everything in the vial.

Then identify the applicable rule year and organization. Our banned-in-sport checker is an educational starting point, not personal clearance. A result for one ingredient or one year cannot automatically clear the whole program.

Save the official response and any instructions from the prescribing clinician. A record of what was checked is more useful than a screenshot of a forum comment saying that a substance is fine. This is especially important when a seller uses an acronym that differs from the scientific name.

What this update does not establish

It does not establish a safe dose, a detection window, a washout interval or an effective performance-enhancement strategy. Those are different questions, and a substance's presence on the list does not answer them. We do not provide a protocol for avoiding detection.

It also does not convert a U.S. compounding decision into international sporting permission. The FDA peptide reclassification guide concerns a separate regulatory process. A product may be discussed in domestic pharmacy policy while still falling within a prohibited anti-doping category.

Finally, it does not mean that every anti-doping summary is equally precise. The official WADA document is the reference for the exact class wording. If a secondary explanation conflicts with that document, check the primary text and seek clarification from the relevant organization.

Preparing for January without changing October's rules

The sensible preparation is a dated review of the products you already use and anything proposed for the next season. Bring that list to the clinician and the anti-doping organization now, while there is time to resolve uncertainty. Do not wait until an event registration to discover that the product name in a clinic chart differs from the ingredient on the list.

During 2026, keep current-year decisions tied to the 2026 document. From January 1, use the 2027 list and check that any saved tools or printouts reflect the transition. A fresh webpage timestamp is not enough; the actual rule year must be visible.

The useful message from the 2027 update is clarity: unapproved peptides cannot be cleared by omission from an examples list, SLU-PP compounds are explicitly addressed under S4, and monitoring of semaglutide and tirzepatide remains a different status from prohibition.